- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech M&A deals that haven't happened because of price argue against the risk of a bubble.
Trade-Ideas LLC identified Onyx Pharmaceuticals (ONXX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Cramer will be watching Washington and a number of stocks.